Featured Stories
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.
In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Latest News
Recent Tweets from ScripAccelerating Cancer Drug Development
Attrition rates in drug discovery and development have been a major bane to the pharmaceutical industry and contribute greatly to the high cost of research and development. These challenges are magnified in oncology. Click the link below and discover how SMEs are delivering oncology breakthroughs and improving preclinical insights.
Formulation In The Drug Product Development Process
Rentschler Biopharma, Leukocare Biotechnology and Pharma Intelligence are undertaking a brief survey to gather insight into the importance, expectations and common challenges of drug product formulation. Each respondent to complete the survey will get a chance to win one of four $50 Visa gift cards.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
It's No Cosentyx/Taltz But Ilumya Pleases Customers, Says Sun
Sun Pharma acknowledged the intense competition that awaits its psoriasis asset, Ilumya (tildrakizumab) in the US, but maintained that the overall profile of the IL-23p19 inhibitor, which is expected to debut in Q2FY19, was “liked” by customers.
CVS Sees Growing Physician, Patient Use Of Real-Time Drug Price Data
Prescribers are reviewing patient benefits information nearly 280,000 times per week while patients are using an online Check Drug Cost tool 250,000 times per month – and the numbers are growing.
Infliximab Success Paves The Way For Adalimumab In Europe
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris
Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.
Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
Venture Funding Deals: Alector, Ascentage, Gossamer And Compass Lead Summer Rounds
Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.
Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability
Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.
Appointments: Senior Hires At Allergan, Novartis, Array Biopharma, Zelluna Immunotherapy, Grail, Alzheon And Sigilon Therapeutics
Pfizer Oncology has lost its CMO to Allergan, while Novartis beefs up its ethical leadership, Array Biopharma appoints a new chair and Sigilon raids Bioverativ for its new CEO.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease
FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use aligns with analyst expectations; panel cites lack of clinical studies in treatment-naive patients and adverse event profile as reasons for limiting drug to patients with limited or no treatment options.
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches
Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal
The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.
Bayer Targets COPD In Haplogen Antiviral Pact
Respiratory viral infections are a frequent cause of COPD exacerbations and the German major is joining forces with the Austrian biotech and Evotec to find new antivirals to tackle the disease.
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.